Ono Pharmaceutical (OTCMKTS:OPHLF) Sees Unusually-High Trading Volume – Time to Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) shares saw strong trading volume on Tuesday . Approximately 1,086 shares traded hands during mid-day trading, an increase of 199% from the previous session’s volume of 363 shares.The stock last traded at $15.63 and had previously closed at $14.90.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Ono Pharmaceutical to a “hold” rating in a research note on Friday, April 17th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Ono Pharmaceutical has a consensus rating of “Hold”.

Ono Pharmaceutical Stock Up 4.9%

The firm has a 50-day moving average of $14.38 and a two-hundred day moving average of $14.65. The firm has a market cap of $7.34 billion, a price-to-earnings ratio of 15.79 and a beta of 0.34. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.